MEI Pharma (NASDAQ:MEIP) Downgraded by Zacks Investment Research to Sell

MEI Pharma} stock has undergone multiple analysts rating changes in the recent past.  MEI Pharma Downgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More MEI Pharma (NASDAQ:MEIP) Downgraded by Zacks Investment Research to Sell